KM
MRTX

Kalos Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kalos Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,250
Closed -$252K – 222
2018
Q2 		$252K Buy
+8,250
New +$312K 0.11% 164
2018
Q1 		– Sell
-12,550
Closed -$232K – 223
2017
Q4 		$232K Buy
12,550
+50
+0.4% +$776 0.11% 182
2017
Q3 		$146K Sell
12,500
-1,500
-11% -$8.68K 0.09% 141
2017
Q2 		$51K Buy
+14,000
New +$53.6K 0.05% 99

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Kalos Management's MRTX Position: Q3 2018 in Review

Kalos Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2018, closing a stake of 8,250 shares — an estimated $252K sold.

Kalos Management first reported a position in MRTX in Q2 2017 and held it in 4 quarters. The position peaked at $252K in Q2 2018. 125 funds tracked by Wall St. Rank hold MRTX as of Q3 2018.

  • Kalos Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Kalos Management sold 8,250 Mirati Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $252K.
  • Kalos Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • Kalos Management's Mirati Therapeutics, Inc. Common Stock position peaked at $252K in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Kalos Management's 13F filing for Q3 2018, filed 14 Nov 2018.